EMEA-002282-PIP01-17-M02 - paediatric investigation plan

Molgramostim

Key facts

• Active Substance:
  Molgramostim
• Therapeutic area:
  • Respiratory, thoracic and mediastinal disorders
  • Pneumology-allergology
• Decision number:
  P/0063/2024
• PIP number:
  EMEA-002282-PIP01-17-M02
• Pharmaceutical form(s):
  Nebuliser solution
• Condition(s) / indication(s):
  Treatment of pulmonary alveolar proteinosis
• Route(s) of administration:
  Inhalation use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  08/03/2024

Decision

P/0063/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for molgramostim, (EMEA-002282-PIP01-17-M02)

AdoptedReference Number: EMA/87258/2024